Home Cart Sign in  
Chemical Structure| 1883545-60-5 Chemical Structure| 1883545-60-5

Structure of CRT0066101 2HCl
CAS No.: 1883545-60-5

Chemical Structure| 1883545-60-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CRT0066101 reduces BrdU incorporation, increases apoptosis, blocks neurotensin (NT)-induced PKD1/2 activation, reduces NT-induced PKD-mediated Hsp27 phosphorylation, attenuates PKD1-mediated NF-κB activation, and abrogates expression of NF-κB-dependent-dependent proliferative and pro-survival proteins.

Synonyms: CRT0066101 dihydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CRT0066101 2HCl

CAS No. :1883545-60-5
Formula : C18H24Cl2N6O
M.W : 411.33
SMILES Code : OC1=CC=C(C2=CN(C)N=C2)C=C1C3=NC=CC(NC[C@H](N)CC)=N3.[H]Cl.[H]Cl
Synonyms :
CRT0066101 dihydrochloride
MDL No. :MFCD30182249
InChI Key :CXYCRYGNFKDPRH-FMOMHUKBSA-N
Pubchem ID :136664697

Safety of CRT0066101 2HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • PKD

    PKD1, IC50:1 nM

    PKD2, IC50:2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
PC3-ML cells 5 µM 22 h Inhibited invasion of PC3-ML prostate tumor cells Am J Pathol. 2023 May;193(5):624-637
PC3-ML cells 5 µM 24 h Inhibited migration of PC3-ML prostate tumor cells Am J Pathol. 2023 May;193(5):624-637
MDA-MB-231 1 µM 12 h Inhibits PRKD3 kinase activity, reduces CLU protein levels Adv Sci (Weinh). 2021 Jan 6;8(4):2003205
MDA-MB-468 1 µM 12 h Inhibits PRKD3 kinase activity, reduces CLU protein levels Adv Sci (Weinh). 2021 Jan 6;8(4):2003205
C4-2B cells 5 µM 24 h Inhibited migration of C4-2B cells Am J Pathol. 2023 May;193(5):624-637
Porcine primary chondrocytes 10 µM 24 h To evaluate the protective effects of CRT0066101 against IL-1β-induced apoptosis and inflammation in chondrocytes. Results showed that CRT0066101 significantly reduced IL-1β-induced cytotoxicity, apoptosis, and inflammation, and restored normal morphology and viability of chondrocytes. Int J Nanomedicine. 2019 Nov 11;14:8835-8846
Human uroepithelial cell line SV-HUC 5 µM 6 days CRT0066101 had minimal effect on the viability of SV-HUC cells, with a viability rate of 92.13%. Cell Mol Life Sci. 2018 Mar;75(5):939-963
Bladder cancer cell line UMUC1 0.625-20 µM 4 days CRT0066101 inhibited the proliferation of UMUC1 cells with an IC50 value of 0.4796 µM. Cell Mol Life Sci. 2018 Mar;75(5):939-963
Bladder cancer cell line TCCSUP 0.625-20 µM 4 days CRT0066101 inhibited the proliferation of TCCSUP cells with an IC50 value of 1.4300 µM. Cell Mol Life Sci. 2018 Mar;75(5):939-963
Bladder cancer cell line T24T 0.625-20 µM 4 days CRT0066101 inhibited the proliferation of T24T cells with an IC50 value of 0.3333 µM. Cell Mol Life Sci. 2018 Mar;75(5):939-963
Bladder cancer cell line T24 0.625-20 µM 4 days CRT0066101 inhibited the proliferation of T24 cells with an IC50 value of 0.4782 µM. Cell Mol Life Sci. 2018 Mar;75(5):939-963
HCC1954 2.5 μM 16 h CRT0066101 significantly reduced the migration and invasion capabilities of HCC1954 cells. Mol Cancer Ther. 2015 Jun;14(6):1306-16
MDA-MB-231 2.5 μM 60 h CRT0066101 significantly reduced the proliferation of MDA-MB-231 cells. Mol Cancer Ther. 2015 Jun;14(6):1306-16
Bone marrow-derived macrophages 2 μM 2 h To investigate the effect of CRT0066101 on LPS-induced TGF-β1 expression, results showed that CRT significantly inhibited TGF-β1 expression. Lab Invest. 2023 Feb;103(2):100018
MiaPaCa-2 cells 2.5 µM 1 hour CRT0066101 inhibited PKD activation in MiaPaCa-2 cells and prevented the increase in CTGF, CYR61, and CXCL5 mRNA levels induced by insulin and neurotensin. Mol Cancer Res. 2017 Jul;15(7):929-941
PANC-1 cells 2.5 µM 1 hour CRT0066101 inhibited PKD activation in PANC-1 cells and prevented the increase in CTGF, CYR61, and CXCL5 mRNA levels induced by insulin and neurotensin. Mol Cancer Res. 2017 Jul;15(7):929-941
THP-1-derived macrophages 2.5 µM 24 h To evaluate the inhibitory effect of CRT0066101 on LPS-induced inflammatory cytokine production. Results showed that CRT0066101 significantly reduced the protein and mRNA levels of LPS-induced cytokines (e.g., IL-6, TNF-α, and IL-1β). Int Immunopharmacol. 2023 Jul;120:110240
GM133 0.5 and 1 μM 3 days Inhibited cell proliferation, with inhibition rates between 45% and 81% Neuro Oncol. 2014 Jul;16(7):933-45
U87MG 0.5 and 1 μM 3 days Inhibited cell proliferation, with inhibition rates between 45% and 81% Neuro Oncol. 2014 Jul;16(7):933-45

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice TNBC cell line xenograft murine models Subcutaneous injection 50 mg/kg Weekly for several weeks Significantly suppresses TNBC tumor growth Adv Sci (Weinh). 2021 Jan 6;8(4):2003205
Athymic NCr-nu/nu mice UMUC1 subcutaneous xenograft model Oral gavage 120 mg/kg 3 times per week for 25 days CRT0066101 significantly inhibited the growth of UMUC1 xenografts, with tumor volumes of 835.83 mm3 in the treated group compared to 1943.08 mm3 in the control group at day 25. Cell Mol Life Sci. 2018 Mar;75(5):939-963
NOD scid mice Orthotopic mammary fat pad tumor model Oral 80 mg/kg Every other day for eight weeks CRT0066101 significantly reduced primary tumor growth and metastasis. Mol Cancer Ther. 2015 Jun;14(6):1306-16
Nude mice HCT116 xenograft model Oral 40, 80, 120 mg/kg Once daily for 3 weeks Significantly inhibited tumor growth, with tumor volume reductions of 55.6%, 65.2%, and 69.5% Mol Cancer Ther. 2014 May;13(5):1130-41
C57BL/6 mice Bleomycin-induced dermal fibrosis model Oral 80 mg/kg Once daily for 4 weeks To evaluate the therapeutic effect of CRT0066101 on bleomycin-induced dermal fibrosis, results showed that CRT significantly reduced dermal thickness, α-SMA, collagen, and IL-6 expression. Lab Invest. 2023 Feb;103(2):100018
C57BL/6 mice LPS-induced acute lung injury model Intraperitoneal injection 10 mg/kg body weight Once every other day for a total of three treatments To evaluate the protective effect of CRT0066101 on LPS-induced acute lung injury. Results showed that CRT0066101 significantly reduced LPS-induced alveolar wall swelling and inflammatory cell infiltration, decreased the number of inflammatory cells in BALF, and lowered the levels of inflammatory cytokines (IL-1β, TNF-α, and IL-6). Int Immunopharmacol. 2023 Jul;120:110240
Nude mice PC3-ML cell bone metastasis model Oral gavage 80 mg/kg Once daily for 4 weeks Inhibited metastasis of prostate cancer cells to bone Am J Pathol. 2023 May;193(5):624-637

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.43mL

0.49mL

0.24mL

12.16mL

2.43mL

1.22mL

24.31mL

4.86mL

2.43mL

References

 

Historical Records

Categories